Skip to main content
Caplight Logo









ReproNovo

ReproNovo

Private
LausanneHealthcare & Life Scienceshttps://repronovo.com/

Last Round

Series A

May 21, 2025

Total Funding Raised

$65M

Company Overview

ReproNovo is a biopharmaceutical company that develops innovative treatments for reproductive medicine and women's health.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

organ preservationorgan perfusionmachine perfusionhypothermic oxygenated perfusionmedical deviceorgan transportationex-vivo perfusionliver preservationtransplantation technologymedtechsingle-use deviceorgan procurement organizationsOPOtransplant centerscold perfusion

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ReproNovo Comparables

Compare ReproNovo with similar companies based on industry and business-model similarity.

ReproNovo comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vivalyx
84%
Bridge to Life
84%
Organ Recovery Systems
79%

ReproNovo Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 21, 2025

Key People

Founding team and executive leadership

BingMei Hao

CFO Co-Founder

Founding Team

Joan-Carles Arce

Chief Scientific Medical Officer Co-Founder

Founding Team

Jean Marie Duvall

Co-Founder And CEO

Founding Team

ReproNovo Investors

Notable investors and investment history

ReproNovo investors
InvestorRounds
ALSA VenturesSeries A
M VenturesSeries A, Seed
Ysios CapitalSeries A
AXA IM AltsSeries A
BNP Paribas Asset ManagementSeries A
Jeito CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 18, 2026

    Monthly visitors grew 291% MoM, reaching 1.6K.

  • May 21, 2025

    $65M Series A round completed.

ReproNovo Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ReproNovo Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ReproNovo's valuation, stock price, and market status.

Firmographic Details

HeadquartersLausanne
Employee Range22
Year Founded2021
Last FundingMay 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?